Figure 3.

Stattic and tocilizumab combination increase pSTAT-3 dephosphorylation in DU145 cells. The cells were cultured with the different treatments according to the corresponding groups for 24 h. (a) IL6R/STAT-3 axis expression was compared between PCa cell lines using 50 μg of protein by Western blot; the presence of constitutive pSTAT-3 expression was shown in the DU145 line only; protein expression was then verified by in-cell Western. (b) Use of treatment with Stt causes a decrease in metabolic activity with concentrations greater than 5 μM. (c) The effective Stt decrease is only shown at concentrations above the IC50. (d) The combined treatments with Tcz allow a lower Stt concentration than the IC50 with greater efficiency in the dephosphorylation of pSTAT-3. All experiments were repeated at least three times. Data are shown as the mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; (unpaired t-test) against the basal group. Stt: stattic; Tcz: tocilizumab.